After worries that their data for their experimental lupus drug wouldn't be up to snuff, Human Genome Sciences is vindicated. According to Bloomberg, Benlysta met the goals of its clinical study, finding that it "was more effective at easing pain, hair loss and skin rash than a placebo." This report sent the company's stock upwards by 200 percent from to $10.01, reports MarketWatch this morning.